Corbion N.V.

Corbion N.V.

CSNVY
Corbion N.V.US flagOther OTC
22.25
USD
- -
- -
1.28BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
10.55
12.46
15.2
15.6
15.35
15.28
16.61
16.75
18.18
24.71
21.4
22.05
21.86
Basic EPS, GAAP
-0.01
-0.33
1.29
1.74
1.46
0.93
0.44
1.24
1.33
1.53
1.23
3.29
1.29
Free Cash Flow per Basic Share
-0.8
-0.02
0.83
1.15
2.03
1.7
1.95
1.85
0.38
0.66
2.8
3.15
2.77
Dividend per Share
0.99
0.09
0.97
0.9
1.04
0.56
0.56
0.56
0.56
0.56
0.56
0.72
0.64
Book Value per Share
5.92
6.26
5.98
6.1
6.36
6.71
6.49
7.1
7.56
8.62
9.4
11.82
12.44
Tangible Book Value per Share
5.78
6.24
5.78
6.17
6.18
6.49
6.06
5.95
6.73
7.83
8.12
11.53
11.27
Basic Weighted Avg Shares
70
62
60
58
58
59
59
59
59
59
59
58
58
Sales/Revenue/Turnover
744
770
918
911
892
897
976
986
1,071
1,458
1,264
1,288
1,267
Operating Margin (%)
5.04
1.68
11.83
13.93
13.72
9.8
6.28
9.12
4.39
7.11
6.53
5.94
9.19
Depreciation Expense
41
44
46
50
45
42
62
60
64
76
85
87
86
Net Income, GAAP
2
-18
80
104
85
54
26
73
78
90
73
192
75
Effective Tax Rate (%)
72.92
1,063.16
21.53
12.13
13.41
22.21
42.28
16.65
9.48
22.68
5.07
26.56
21.18
Profit Margin (%)
0.3
-2.38
8.73
11.37
9.49
6.05
2.64
7.41
7.31
6.17
5.77
14.92
5.9
Working Capital
186
132
197
200
133
90
25
151
184
62
-9
75
273
LT Debt
94
36
154
133
117
134
169
284
419
437
417
308
348
Total Equity
505
509
488
498
489
520
529
516
554
626
636
772
743
Return on Invested Capital (%)
1.01
-20.34
12.86
16.31
15.84
9.44
4.26
8.58
4.41
6.51
5.53
4.13
7.39
Return on Capital (%)
0.65
-13.23
15.98
20.26
17.21
10.71
4.94
11.38
10.66
9.31
7.75
16.41
7.38
Return on Common Equity (%)
-0.11
-5.15
20.86
28.3
23.31
14.22
6.65
18.27
18.14
18.88
13.7
30.85
10.59

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.54%
7.91%
-3.87%
Free Cash Flow
42.13%
63.49%
-12.6%
Net Income, GAAP
21.15%
21.12%
-61.08%
Sales/Revenue/Turnover
3.93%
6.34%
-1.61%
Total Cash Common Dividend
- -
- -
-11.22%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,288
2025
- -
- -
- -
- -
1,267
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.29
2025
- -
- -
- -
- -
1.29
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.72
2025
- -
- -
- -
- -
0.64
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Olivier Rigaud
Full Time Employees
2,383
Sector
Basic Materials
Industry
Chemicals - Specialty
Address
Piet Heinkade 127 Amsterdam Netherlands 1019 GM
IPO Date
Jan 19, 2011
Business
Corbion N.V. (CSNVY) manufactures and markets sustainable biobased ingredients, specializing in lactic acid and its derivatives, food preservation solutions, functional blends, algae ingredients, and biochemicals derived from fermentation processes; its core offerings span emulsifiers, enzymes, antioxidants, mold inhibitors, omega-3 algae products, and lactides for applications in food preservation, bakery, meat, dairy, animal nutrition, home and personal care, pharmaceuticals, medical devices, bioplastics, electronics, and packaging. The company operates globally with production facilities in Europe, North America, Asia, and Latin America, targeting food manufacturers, biochemical processors, and industrial customers seeking natural and sustainable solutions. Founded in 1919 and headquartered in Amsterdam, Netherlands, Corbion lists on Euronext Amsterdam and reported €1,332.0 million in annual sales for 2024 with 2,399 full-time employees. Recent developments include a strategic partnership with BRAIN Biotech AG announced in August 2025 to advance nature-based ingredient technologies; a collaboration with Kuehnle AgroSystems for algae-based innovations; the launch of Verdad Essence WH100 natural mold inhibitor and innovative egg replacers in April 2025 to address bakery supply challenges; expansion of the partnership with IMCD for specialty chemicals distribution; acquisition of a bread improver business from Novotech to strengthen its Indian market presence; multiple share buyback programs totaling up to €30 million in 2024-2025; a USD 100 million debt issuance via US Private Placement in 2025; facility upgrades in Mexico and new product introductions for refrigerated foods and AI-enhanced Listeria control models; and executive changes such as the appointment of Masha Vis-Mertens as Chief Human Resources Officer in 2024.

Company News

APIChat
  • Corbion N.V. (CSNVY) Q1 2026 Earnings Call Transcript

  • Corbion N.V. (CSNVY) Q4 2025 Earnings Call Transcript

  • Corbion N.V. (CSNVY) Analyst/Investor Day Transcript

  • Corbion reports the progress of its share buyback program 6 October – 10 October 2025

  • Corbion reports the progress of its share buyback program 29 September – 3 October 2025

  • Corbion joins the Ferment4Health Project to unlock the gut health potential of fermented foods

  • Corbion General Shareholders Meeting approves Board (re)appointments and dividend

  • Corbion N.V. (CSNVF) Q4 2024 Earnings Call Transcript